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ABSTRACT 
 
 
 The role of estrogen in breast cancer has been recognized for decades. The 
selective estrogen receptor modulator tamoxifen was the first targeted therapy for the 
treatment of breast cancer. It was also the first drug approved by the FDA for the 
reduction of breast cancer risk. While tamoxifen has extended the lives of countless 
patients with breast cancer, resistance to tamoxifen remains a significant clinical 
problem. Work over the last two decades has greatly enhanced our understanding of the 
molecular mechanisms by which breast cancer cells may become resistant to tamoxifen 
treatment. Here I review our current understanding of the tamoxifen’s mechanism of 
altering estrogen signaling along with the current experimental and clinical work 
investigating the mechanisms by which breast cancer cells develop resistance. 
Elucidation of the molecular mechanisms underlying tamoxifen resistance will allow 
improvement of treatment by potentially enhancing the effects of tamoxifen while 
reducing the incidence of resistance. 
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CHAPTER 1.  INTRODUCTION 
 
 
 The American Cancer Society estimates that in 2009, 192,370 new cases of 
invasive breast cancer and 62,280 additional cases of in situ breast cancer were diagnosed 
among women, as well as approximately 40,170 deaths resulting from breast cancer [1]. 
Treatments for breast cancer include surgery, radiation therapy, and systemic therapy. 
Surgery is aimed at removing the cancer from the breast and assessing the stage of 
disease, where as radiation therapy may be used to destroy the cancer cells remaining 
after surgery. Systemic therapy may be neoadjuvant, often used to reduce the size of the 
tumor before surgery, or adjuvant to kill remaining undetected cancer cells. Systemic 
therapy includes biologic therapy, chemotherapy, and hormone therapy. Endocrine 
therapy is primarily aimed at interfering with estrogen signaling because of the important 
role estrogen plays in many breast cancers. Tamoxifen was the first targeted therapy for 
breast cancer as well as the first preventative, however resistance remains a significant 
issue. A clearer understanding of the molecular mechanisms by which resistance 
develops may prevent its occurrence and optimize treatment of patients with breast 
cancer. 
 
 
1.1. Endocrine Therapy for Breast Cancer 
 
 The relationship between hormone therapy and breast cancer was first 
acknowledged over a century ago when surgeon Sir George Beatson preformed an 
oophorectomy on a patient with advanced breast cancer and observed a dramatic response 
[2]. He had no knowledge of the estrogen receptor, but simply noted that removing the 
ovaries, the major source of estrogen, could benefit women at the inoperable stage of 
disease. The estrogen receptor (ER) was reported in 1973 [3] and the association between 
the risk of breast cancer and elevated estrogen has been consistently found in many 
subsequent studies [4]. Estrogen stimulates the proliferation of breast epithelial cells, and 
has been implicated in the pathogenesis of breast cancer [5]. 
 
A meta-analysis of 51 epidemiologic studies enrolling 161,116 women 
investigated the relation between risk of breast cancer and use of hormone replacement 
therapy and showed that breast cancer risk increased by 2.3% per year of hormone use 
compared with an increased risk of 2.8% per year of natural delay in the onset of 
menopause [6]. These results imply that hormone use increases the risk of developing 
breast cancer and support the role of estrogen in the pathogenesis of breast cancer. 
However, before the introduction of pharmacological agents, endocrine therapy for breast 
cancer was ablative to remove sources of estrogen by either surgery or radiotherapy [7].  
 
Allen and Doisy first discovered the estrogenic hormones produced in the ovary 
[8]. The discovery of estrogen led to questions regarding the mechanism by which 
estrogens exert their tissue specificity and if there is a target to block estrogen action. 
Previously it was believed that estrogens exert their actions by participating in enzymatic 
processes. However, the identification of the estrogen receptor that mediates the diverse 
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actions of estrogen without alteration of the hormone itself provided a mechanism to 
describe the specificity of action and opened the door to molecular targeting in the 
treatment and prevention of breast cancer [9]. Two thirds of breast cancers express the 
estrogen receptor, therefore, ER-targeted therapy is widely used in breast cancer to inhibit 
signaling through ER and disrupt breast cancer growth [10]. 
 
 
1.2. Estrogen Signaling 
 
Estrogen and estrogen receptors are key regulators of breast epithelial 
proliferation, differentiation, and apoptosis [11]. Estrogens are cyclopentanophenanthrene 
compounds whose synthesis begins with cholesterol like other sex and adrenal hormones. 
The most potent and abundant estrogen in humans is 17-estradiol (E2), but estrone and 
estriol are also present at lower levels [12]. Because of their steroid structure, estrogens 
can diffuse passively through the cytoplasmic and nuclear membranes in order to interact 
with its nuclear receptor. Estrogen plays a broad role in human physiology and has been 
implicated in the development or progression of numerous diseases, such as various types 
of cancer, osteoporosis, neurodegenerative and cardiovascular diseases, insulin 
resistance, lupus erythematosus, endometriosis, and obesity [13]. Two molecular forms of 
the estrogen receptor (ER) have been identified, and ER acts as a transcriptional factor 
and also interacts with other transcriptional factors and growth factor-dependent kinases. 
 
 
1.2.1. Estrogen Receptor Subtypes 
 
Estrogen mediates its effects via receptors, which serve as the basis for many 
therapeutic interventions. ER is a ligand-activated transcription factor. It belongs to a 
superfamily of nuclear receptors that includes other steroid hormone receptors. Jensen 
and Jacobsen first demonstrated the existence of this receptor that could bind 17-
estradiol in the late 1950s, and the first ER was cloned in 1986 [14]. It was believed this 
was the single receptor until Kuiper et al. cloned another ER in 1996 from a prostate 
cDNA library. Today, the two estrogen receptors are designated ER and ER. The two 
proteins are produced by two distinct genes on different chromosomes and display tissue 
specific expression, with overlapping distribution: “ER is more expressed in prostate, 
bone, ovaries (granulosa cells), lungs, and in various parts of the central and peripheral 
nervous system, while ER is predominantly expressed in the pituitary gland, ovaries 
(thecal and interstitial cells), uterus, liver, kidneys, adrenals, and the mammary glands” 
[15]. It is important to note that both subtypes are expressed in the breast.  
 
ER/ are proteins sharing common regions, designated A/B, C, D, E, and F. 
These regions participate in the formation of independent but interacting functional 
domains [12]. Figure 1-1 shows the well-defined domain organization of the two 
receptors, which show a high degree of similarity at the amino acid level, as well as the 
degree of homology in the specific domains. The A/B domain includes the activation 
function 1 (AF1), which is the “region responsible for the constitutive and ligand- 
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Figure 1-1. Human ERα and ERβ nuclear receptors. A schematic representation of 
the structure of human ERα and ERβ is depicted. The numbers outside each box refer to 
the amino-acid number, and the percentage of amino-acid homology for each domain is 
also shown. The location of each domain on each receptor is designated. 
 
Reprinted with permission. Zilli, M., et al., Molecular mechanisms of endocrine 
resistance and their implication in the therapy of breast cancer. Biochim Biophys Acta, 
2009. 1795(1): p. 62-81 [15].  
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independent transcriptional activity of ER.” The C domain contains the DNA-binding 
domain (DBD) and is also important for receptor dimerization. The D domain is a 
flexible hinge with a nuclear localization signal, and the E domain is the ligand-binding 
domain (LBD) and “harbors a second nuclear localization signal and the activation 
function 2 (AF2) responsible for the ligand-dependent activation of ER.” The F domain is 
not essential and plays a complex modulatory role on both activities [15].  
 
 Soon after the identification of ER, it was demonstrated that several compounds 
show receptor selectivity in binding and/or efficacy, and studies have since shown that 
ER and ER have distinct biological activities. ERα is the stronger transcriptional 
activator of the two ER isoforms, at physiological concentrations of estradiol, co-
expression of ERβ results in suppression of both the efficacy and the potency of 
hormone-stimulated responses, and therefore the relative expression levels of the two 
isoforms are an important determinant of cellular sensitivity to estrogens [16].  
 
Many compounds could no longer be classified simply as “estrogenic” after the 
identification of the tissue specific actions of estrogens and the discovery of the role of a 
second estrogen receptor. ER ligands do not stimulate uterine growth or induce the 
progesterone receptor in the uterus, and ER ligands do not inhibit prostatic growth, and 
the term “selective estrogen receptor modulator” (SERM) was introduced to provide a 
more generic description of the activity of an ER ligand [14]. 
 
 
1.2.2. Genomic ER Signaling 
 
 Estrogen influences the physiology of many target tissues and the long-term 
effects of estrogen are mediated predominantly via ERs functioning as DNA-binding 
transcription factors. ERs regulate gene expression by both direct (classical) and indirect 
(non-classical) binding of an ER to DNA (Figure 1-2). These pathways are referred to as 
genomic or “nuclear-initiated steroid signaling (NISS)” pathways [15]. Tissue-specific 
responses are a result of the regulation of different genes by ER. 
 
 
1.2.2.1. Classical Genomic Mechanism 
 
 ERs predominantly exist as monomers bound to heat shock proteins in the cell 
nucleus. However, estrogen diffuses into the nucleus and binds to ER leading to 
conformational changes, phosphorylation and disassociation from the chaperon proteins 
and finally dimerization [17]. The ER dimmer may then bind to an estrogen response 
element (ERE) upstream of estrogen-dependent genes in the regulatory regions of target 
genes. The consensus palindromic ERE was initially described based on the estrogen-
responsive sequence from estrogen-responsive genes from the Xenopus laevis A2 
promoter: 5’-GGTCAnnnTGACC-3’, but the human genome possesses imperfect 
palindromic sequences in their promoter with 3,4, and 5 bp spacers [12].  
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Figure 1-2. Estrogen receptor signaling pathways. This illustrates the genomic or 
“nuclear-initiated steroid signaling” (NISS) pathways and the non-genomic or 
“membrane-initiated steroid signaling” (MISS) pathway and the mechanisms by which 
they regulate cell growth.  
 
Reprinted with permission. Zilli, M., et al., Molecular mechanisms of endocrine 
resistance and their implication in the therapy of breast cancer. Biochim Biophys Acta, 
2009. 1795(1): p. 62-81 [15].  
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1.2.2.2. Non-Classical Genomic Mechanism 
 
 ERs may also influence gene expression without directly binding to DNA by 
interacting with other transcription factors. Such factors include Fos/Jun activating 
protein (AP-1) complex, cyclic AMP-response elements (CREs), and Sp1 sites and, this 
is the mechanism by which estrogen regulates cyclin D1 and IGFR1 [15].  
 
Via both the classical and non-classical mechanisms, estrogen results in a general 
up-regulation of genes regulating cell proliferation and survival and the down-regulation 
of genes with anti-proliferative or pro-apoptotic activity and the final result growth 
stimulation and apoptosis suppression [18]. Up-regulation is mediated by the two 
transactivation domains mentioned above: AF-1 (A/B domain) and AF-2 (E domain). 
AF-1 activity is regulated by phosphorylation and is hormone-independent, while AF-2 is 
in the ligand-binding domain and therefore hormone-dependent [17].  
 
Estrogen-bound ER can directly or indirectly induce gene transcription only if 
AF1 and/or AF2 are activated, and either domain may be dominant depending on the 
cellular environment or the specific promoter type, but generally the two act in synergy 
[15]. Ligand binding results in a conformational change of ER that uncovers AF-2 and 
that exposes a binding surface for further modulation by co-regulatory proteins. The 
binding of co-activators enhances the transcriptional activity by forming large complexes 
that may recruit histone-acetyltransferase (HAT) leading to chromatin decondensation, 
while co-repressors reduce transcription by recruiting histone-deacetylase (HDAC) to the 
promoter site resulting in chromatin condensation [15]. The co-regulatory proteins 
recruited are affected by the ER conformation which is dependent on the ligand and the 
specific ERE sequence to which the ER is bound [19].  
 
Unlike AF-2, AF-1 is ligand independent and activated by phosphorylation at 
serine residues subsequent to activation of kinase pathways triggered by growth factor 
receptors [15]. Epidermal growth factor receptor (EGFR), insulin-like growth factor-1 
receptor (IGFR), and human epidermal growth factor receptor type 2 (HER2) have been 
implicated in this mechanism [17]. The mechanism by which estrogen affects AF-1 is not 
well understood at this point. It is important to note that in the absence of estrogen, 
minimal phosphorylation is responsible for constitutive AF-1 activity and that growth 
factor signaling pathways can directly activate ER and subsequent transcription. The 
growth factor signaling will be explained further in Section 3.2.2. as a potential 
mechanism of resistance to endocrine therapy.  
 
 
1.2.3. Non-Genomic Mechanism 
 
 The membrane-initiated steroid signaling (MISS) pathway is a rapid (in seconds 
to minutes) non-genomic mechanism of action, mediated by membrane-associated ER. 
This occurs via a population of ERs that exists within caveolar rafts and other domains in 
the plasma membrane. ER is associated with caveolin-1 and a variety of proximal 
signaling molecules, including G proteins, Src and Ras, and B-Raf. Activation of these 
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ERs results in signal cascades from G protein activation. Similarly to many other G 
protein coupled receptors, G protein activation by ER leads to the cell-specific 
stimulation of phospholipase C, protein kinase C, ERK, or phosphatidylinositol 3-kinase 
and nitric-oxide synthase [20]. The activation of these kinases has the ability to activate 
growth factors and cytoplasmic kinases, which may in turn phosphorylate ER and its co-
regulators. This suggests that the non-genomic and genomic activities are complementary 
and potentially synergistic [15]. Non-genomic activity is highly dependent on ligand and 
is regulated by co-regulatory proteins. The activity is also strongly dependent on the 
signal transduction pathways operating within the cell [15].  
 
 
1.3. Therapeutic Approaches to Target Estrogen Activity 
 
The search for pharmacologic means of antagonizing the biological effects of 
estrogen as a therapeutic strategy for women with breast cancer has been ongoing ever 
since the link between human breast cancer and estrogen emerged. A strategy to 
antagonize estrogen in an attempt to treat/prevent breast cancer may have a severe impact 
on a patient’s health by interfering with the significant physiological roles of estrogen in 
reproductive tissues, bone, the cardiovascular system and its role in cognitive function 
and behavior [21].  
 
 “Hormone-receptor (HR) status is an important factor used to determine the 
prognosis and treatment of breast cancer” [22]. HR-positive breast cancer may be ER-
positive, Progesterone-Receptor–positive or both, and typically responds to treatments 
that specifically block or interfere with the function of estrogen or progesterone. 
Sensitive tumors are now identified by testing for specific receptors, the degree of 
positivity scored, and taken into account when determining a course of therapy. Of 5,993 
mammary carcinomas examined by immunohistochemistry by Nadji et al., 75% were 
positive for ER and 55% of all tumors reacted positively for PR. All PR-positive tumors 
were also positive for ER, and endocrine therapy is indicated as part of adjuvant 
treatment for these tumors [23]. There are now several effective options for the treatment 
of hormone-receptor positive breast cancer and include selective ER modulators 
(SERMs), aromatase inhibitors, and selective ER down-regulators (SERDs). 
 
 
1.3.1. SERMs 
 
 SERMs exert selective agonist or antagonist effects on various estrogen sensitive 
tissues. They are a chemically diverse group of compounds that lack the steroid structure 
of estrogens, and although the primary structure of SERMs differ strikingly from that of 
estrogens (Figure 1-3), they have a tertiary structure that permits their binding to the 
ligand-binding domain of the ER [24]. Several of these drugs have been available for 
decades, but their tissue-specificity in humans has only recently been acknowledged. The 
current clinically available SERMs are Tamoxifen, Toremifene, and Raloxifene, and they 
differ slightly in their actions and side effects. The specific mechanism of actions of 
SERMs with focus on Tamoxifen will be discussed in greater detail in Section 2. 
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Figure 1-3. Chemical structures of 17-Estradiol and the three FDA-approved 
SERMs. 
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1.3.2. Aromatase Inhibitors 
 
 Anti-aromatase agents inhibit the cytochrome P-450 component of the aromatase 
enzyme complex, which is responsible for the final step of estrogen biosynthesis. These 
drugs are classified into generations, and the third-generation agents are currently 
approved for use in the treatment of breast cancer. These are further divided into type I 
and type II: Type I inhibitors (exemestane) have a steroidal structure similar to androgens 
and inactivate the enzyme irreversibly by blocking the substrate-binding site, while Type 
II inhibitors (anastrozole and letrozole) are non-steroidal and their action is reversible 
[25]. 
 
 
1.3.3. SERDs 
 
 SERDs are also termed ‘pure anti-estrogens,’ and only fulvestrant is being used 
clinically. It is showing promising clinical activity in the treatment of advanced breast 
cancer. Fulvestrant has a higher affinity for the estrogen receptor (ER) compared to 
SERMs, but does not have any of the agonist activities [21]. Fulvestrant is a novel ER 
antagonist that binds to the receptor and prevents ER dimerization, leading to rapid 
degradation and loss of cellular ER expression [26].  
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CHAPTER 2. TAMOXIFEN 
 
 
2.1. History 
 
 For more than 30 years, tamoxifen has been the gold standard for the endocrine 
treatment of ER-positive breast cancer, and it is estimated that more than 400,000 women 
are alive today as a result of tamoxifen therapy, and millions more have benefited from 
palliation and extended disease-free survival [27]. The discovery of non-steroidal anti-
estrogens by the pharmaceutical industry during the 1960s was initially an exciting 
prospect for ‘morning after’ anti-fertility agents. Unfortunately, unlike in the rat, the anti-
estrogens actually improved fertility by inducing ovulation in subfertile women [28]. The 
discovery of the ER in the 1970s and the relationship between estrogen and breast cancer 
provided a target in the treatment and prevention of breast cancer. At this point research 
into anti-estrogens previously abandoned as anti-fertility agents was revived.  
 
 In the laboratory, tamoxifen was demonstrated to prevent the induction of 
carcinogen-induced rat mammary tumors and was shown to have efficacy in the 
treatment of advanced breast cancer and became the first targeted therapy for breast 
cancer when it was approved in 1977 for the treatment of women with metastatic breast 
cancer [29].  Over time the widening use of tamoxifen for long-term treatment and the 
reduction in the risk of contralateral breast cancer in adjuvant trials led to the evaluation 
of its use as a preventative for breast cancer. In 1992, the National Surgical Adjuvant 
Breast and Bowel Project (NSABP) implemented a randomized clinical trial to evaluate 
tamoxifen’s potential in the prevention of breast cancer in 13,800 high risk women and 
found that breast cancer incidence was reduced by 50% in tamoxifen-treated women 
compared to placebo treated controls [30]. In 1999, the Food and Drug Administration 
approved tamoxifen for the reduction of breast cancer risk, and later, it was the first drug 
approved for the prevention of any cancer. The reinvention of tamoxifen from a failed 
“morning after pill” to the first targeted therapy for breast cancer and first 
chemopreventive provided the clinical research community with an invaluable new 
therapeutic tool to pioneer the strategy of long term anti-hormonal therapy and 
chemoprevention [31].  
 
 
2.2. Mechanism of Action 
 
 The mechanisms of tissue selective, mixed agonist-antagonist action of tamoxifen 
and other SERMs are still being determined, but the unique actions may be explained by 
interactive mechanisms. The fundamental elements that factor into the tissue-selective 
actions are the differential estrogen-receptor expression in a given target tissue, the 
differential ER conformation on ligand binding, the precise sequence compositions of the 
EREs, and the differential expression and binding of co-regulator proteins to the estrogen 
receptor [24]. Because of their distinct biological activities the relative expression of ER 
and ER in different tissues will affect the response to both estrogens and tamoxifen.  
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As explained in 1.2.1, ER and ER have distinct biological activities and ER 
can in fact suppress the actions of ER by forming a heterodimer with it. Thus, the 
relative levels of expression of these two receptor isoforms will affect the cellular 
responsiveness to estrogens. Tamoxifen binds to both isoforms and affects the cellular 
responsiveness of each [32]. SERMs function as pure antagonists at ER on genes 
containing estrogen response elements but function as partial agonists when acting via 
ER [16]. 
 
Recently, it has been demonstrated via protein crystallography and surface 
probing techniques that binding of tamoxifen to ER results in a unique conformational 
change.  When estrogen binds to the hydrophobic pocket of ER, the pocket is closed by 
helix 12 of the protein resulting in the activation of AF-2, but when tamoxifen binds to 
the pocket, it prevents reorientation of helix 12 [33]. The precise composition of the 
ERE’s can also alter the structural conformation of the receptor. 
 
 Many co-regulator proteins bind to ER and modulate ER function. As ER 
regulates the rate of gene transcription through its association with co-regulators, the 
overall balance of expression levels of co-activators and co-repressors have been shown 
to be an important determinant of the tissue-specificity of SERMs (Figure 2-1). For 
example, tamoxifen recruits a co-activator complex to ER genes in endometrial cells 
where it acts as an agonist, but a co-repressor complex to the same gene in the breast 
where it acts as an antagonist [34]. Figure 2-1 is a schematic representing the role of co-
regulators in modulating receptor conformation and activity. When tamoxifen binds the 
receptor, the receptor adopts an intermediate partial conformation that is neither fully 
active nor fully inactive. In the intermediate conformation, the receptor is also subject to 
interactions with the relative intracellular concentrations of preferred co-activators or co-
repressors for its activity [32]. Depending on the unique receptor conformation induced 
by ligand binding, varying combinations of co-regulator proteins interact with the 
estrogen receptor and modulate its function in a variety of ways [24].  
 
  
2.3. Treatment of Breast Cancer 
 
Tamoxifen acts as an estrogen antagonist for the breast, and the tissue selective 
actions made it the gold standard treatment for ER-positive breast cancer. By acting as a 
weak ER agonist in the bone, tamoxifen reduces bone loss. Treatment also induces a 
beneficial serum lipid profile by decreasing LDL levels. However, tamoxifen therapy is 
also associated with an increase in the risk of endometrial cancer because of its actions as 
a partial agonist in the endometrium. Nevertheless, there have been numerous studies 
demonstrating efficacy for the treatment and prevention of ER-positive breast cancer. 
Tamoxifen is mainly cytostatic and acts by slowing the proliferation of breast cancer cells 
by inhibiting their progression from the G1 phase of the cell cycle, but it has also been 
shown to induce apoptosis in vitro in breast cancer cell lines and therefore may possess 
cytocidal properties in vivo as well [24]. 
 
Adjuvant tamoxifen therapy has been demonstrated to significantly reduce the 
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Figure 2-1. The potential actions of co-regulators at the ER. The schematic 
demonstrates the potential contributions of co-activators and co-repressors to the tissue-
specific activities of a SERM.  
 
Reprinted with permission. Jordan, V.C. and B.W. O'Malley, Selective estrogen-receptor 
modulators and antihormonal resistance in breast cancer. J Clin Oncol, 2007. 25(36): p. 
5815-24 [32].  
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risk of recurrence and death from breast cancer. A review of 55 clinical trials of adjuvant 
therapy with 37,000 women with breast cancer examined tamoxifen versus no tamoxifen 
before recurrence. The proportional reduction in recurrence was 47% after 5 years of 
treatment with tamoxifen and the proportional reduction in mortality was 26% after 10 
years [35]. The absolute improvements in 10-year survival were 10.9% in lymph node-
positive and 5.6% in lymph node-negative breast cancer, and women with ER–negative 
cancer had very limited benefit [24]. As discussed in Chapter 2.1, the widening use of 
long-term tamoxifen treatment led to its inclusion in randomized primary-prevention 
trials, and the NSABP trial demonstrated a 50% reduction in the risk of breast cancer in 
high risk patients when compared to placebo treated controls [30].  
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CHAPTER 3. MECHANISMS OF RESISTANCE 
 
 
 Despite the relative safety and significant anti-neoplastic and chemopreventive 
activities of tamoxifen, most initially responsive breast tumors develop resistance [33]. 
The development of resistant tumors remains a major obstacle in the struggle to treat and 
prevent breast cancer. Approximately 30% of ER-positive breast cancers do not respond 
to tamoxifen treatment (de novo resistance), and of the tumors that initially respond to 
treatment, the majority develops resistance over time (acquired resistance), despite the 
continued expression of ER. Studies have shown that ER continues to regulate tumor 
development in most resistant cases and the majority are still responsive to fulvestrant 
and AIs, indicating that estrogen remains an important regulator of tumor growth [11]. 
Drug resistance to anti-hormonal therapy in breast cancer was originally viewed as the 
ER-negative cells overgrowing ER-positive cells whose growth had been arrested from 
tamoxifen treatment; however, this view is no longer accepted. It is unlikely that one 
single mechanism can explain hormonal resistance in all breast cancer patients, but recent 
work has provided details about the types of resistance and the mechanisms by which 
they may develop. 
 
 Three classes of resistance are acknowledged: metabolic resistance, intrinsic (or 
de novo) resistance, and acquired resistance [32]. Tamoxifen is a prodrug that is 
metabolically activated. Generated via CYP3A4/5 and CYP2D6 (Figure 3-1), 4-
hydroxytamoxifen and especially endoxifen are important active metabolites of 
tamoxifen that are necessary to achieve the maximal anti-estrogenic and antitumor effects 
of tamoxifen. These metabolites have been shown to posses a 100-fold greater affinity for 
ER and 30- to 100- fold greater potency in suppressing ER-dependent proliferation and 
gene expression [15]. Wide variations in both of these enzymes responsible for tamoxifen 
metabolism exist in the population and the clinical response to tamoxifen therapy is likely 
to depend on the cumulative effect of these metabolites [36]. The clinical relevance of 
these variants on patient outcomes in the treatment of breast cancer with tamoxifen is 
unclear and must be addressed in large populations and with prospective studies [37].  
 
Intrinsic resistance is exemplified by tumors that fail to respond to initial 
tamoxifen therapy, while acquired resistance develops over the time course of tamoxifen 
therapy. The remainder of this review will focus on these types of resistance. Such 
mechanisms include modifications of ER status and alterations in the intracellular 
environment via changed expression of co-regulators and the influence of kinase and 
growth factor signaling. 
 
Tamoxifen’s effects are mediated via the ER, and therefore the degree of 
expression of ER is a strong predictor of response to tamoxifen treatment, and the status 
of ER expression is critical [17]. As explained previously, tamoxifen acts as an antagonist 
at ER, but may act as an agonist to ER. The loss of expression, mutation or change in 
activity of ER, as well as an alteration in the expression of ERβ are potential 
mechanisms by which ER status may change, thus affecting tamoxifen’s actions and 
resulting in the development of clinical resistance. 
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Figure 3-1. The metabolism of tamoxifen. Tamoxifen is metabolized via CYP3A4/5 
and CYP2D6 to its active metabolites 4-hydroxytamoxifen and endoxifen.  
 
Reprinted with permission. Jordan, V.C., New insights into the metabolism of tamoxifen 
and its role in the treatment and prevention of breast cancer. Steroids, 2007. 72(13): p. 
829-42 [37]. 
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3.1. Estrogen Receptor Status 
 
  
3.1.1. Loss of ERα Expression 
 
 The expression of ER has long been regarded as a strong predictor of clinical 
response to tamoxifen and any anti-estrogen therapy. Anti-estrogen therapies are only 
effective in cancers that are ER-positive and dependent on ER signaling for growth and 
proliferation. Loss of ER may confer resistance to any anti-estrogen therapy, and the 
lack of ER expression is the primary mechanism of de novo or intrinsic resistance to 
tamoxifen [15]. The large majority of ER-negative breast cancer tumors demonstrate 
intrinsic resistance, but a small percentage of ER-negative tumors that are progesterone 
receptor (PgR) positive respond to anti-estrogen treatment. PgR is considered another 
important indicator of anti-estrogen response because studies show that roughly 70% of 
ER-positive/PgR-positive tumors effectively respond to tamoxifen, while only 34% of 
ER-positive/PgR-negative tumors respond [11]. “The predictive power of PgR 
expression is likely related to the ability of estrogens to induce its expression. Thus, the 
presence of both ER and PgR may reflect the existence of an at least partially functional 
ER signaling pathway” [38]. 
 
Alterations of the ER gene in the form of point mutations, deletions, or 
insertions are rare events that do not explain the ER-negative status of 20–30% of breast 
cancers and epigenetic mechanisms are now being investigated [39]. Work in cultured 
human breast cancer cells previously demonstrated that the absence of ER gene 
expression is associated with an increased capacity to methylate DNA, as well as 
extensive methylation of CpG islands of the ER gene. These results suggest that 
abnormal methylation may account for transcriptional inactivation [40]. Other work 
suggests that increased deacetylation of histones via HDAC may result in the loss of ER 
expression.  
 
 It was once thought that the loss of ER expression may be responsible for 
acquired resistance to tamoxifen, but only a relatively small percentage of tumors with 
acquired resistance do not express ER [41]. Many tamoxifen resistant patients will still 
respond to second line anti-estrogen treatment with fulvestrant or an aromatase inhibitor 
indicating a continued role of estrogen and the ER in the progression of the cancer. 
 
 
3.1.2. Mutations to ERα 
 
 Several studies have demonstrated that mutations of ER can confer resistance to 
tamoxifen. A naturally occurring mutation of ER has been identified that results in 
increased estrogen sensitivity and increased proliferation at lower estrogen concentrations 
[42]. However, it has been reported that only 1% of the primary breast cancers have point 
mutations in the ER gene [43]. Therefore such mutations of ER are unlikely to contribute 
significantly to the development of resistance to tamoxifen. These types of point 
mutations as well as deletions, duplications, insertions and alternative splicing events 
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have the potential to regulate ER function and therefore should be considered, but 
resistance commonly develops in their absence. 
 
 
3.1.3. Altered Expression of ERβ 
 
 The data regarding the expression level of ER and tamoxifen resistance is 
conflicting. As discussed previously, ER has the ability to repress the activity of ERα 
[44]. Studies have reported low levels of ER to be predictive of tamoxifen resistance, 
while others have shown high levels of ER in resistant breast cancer cells [15]. Like 
ERα, ER expression in breast cancer is associated with a better prognosis. However, the 
contrasting results of studies make a conclusion regarding the role of ER in tamoxifen 
resistance unfeasible at this point in time, and more work is necessary to establish 
whether ER expression is important in tamoxifen resistance. 
 
 
3.1.4. ER Phosphorylation 
 
ER is a target of serine, threonine and tyrosine phosphorylation, and ER 
phosphorylation is a key element of non-genomic actions in response to estrogen, but has 
also been shown to affect genomic transcription mediated events [11]. Introduction of 
mutations at these sties of phosphorylation often results in enhancement of ER 
transcriptional activity. The kinases that mediate these phosphorylations include Src, 
PAK1, PKA, cyclin A, AKT and ERK1/2. Many of the potential mechanisms discussed 
below alter the phosphorylation and thereby the activity of ER possibly contributing to 
the resistant phenotype. 
 
 
3.2. Co-regulator Expression 
 
 Co-regulators play an important role in mediating the transcriptional activity of 
ER. Because many of these may be present at rate-limiting levels in the nucleus, changes 
in their level of expression and/or activity can lead to alterations of ER signaling [15]. In 
particular, over expression of co-activators and down regulation of co-repressors may 
contribute to tamoxifen resistance. “An imbalance in the expression of co-activator and 
co-repressor genes may impair tamoxifen activity either by abolishing the anti-estrogenic 
effect or by switching the effect from anti-estrogenic to estrogenic,” but few studies have 
been studied the role of co-regulators in tamoxifen resistance [45]. 
 
 
3.2.1. Co-activators 
 
 In vitro studies have demonstrated that increased co-activator expression can 
enhance the agonist activity of tamoxifen. AIB1(also called SRC-3, RAC3, ACTR, and 
p/CIP) is an ER co-activator thought to be important in breast cancer. AIB1 is 
phosphorylated and activated by mitogen-activated protein kinases (MAPKs), and high 
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levels of activated AIB1 may potentially reduce the antagonist effects of tamoxifen, 
especially in tumors that also over-express the HER-2 receptor, a member of the 
epidermal growth factor (EGF) receptor family that activates MAPKs [46]. A1B1 is over-
expressed in over 50% of breast tumors [47], and enhances the agonist effect of 
tamoxifen in vitro [48].   
 
A retrospective study investigated the hypothesis that tumors with a relatively 
high abundance of AIB1 are less responsive to tamoxifen therapy in 187 patients having 
received adjuvant tamoxifen and 119 patients with no adjuvant treatment. High AIB1 
expression in patients not receiving adjuvant tamoxifen therapy was associated with 
better prognosis and longer disease free survival. In contrast, for patients who did receive 
tamoxifen therapy, high AIB1 expression was associated with worse disease free 
survival, which may be indicative of tamoxifen resistance [46]. Patients with tumors 
expressing high levels of both AIB1 and HER-2 had worse outcomes with tamoxifen 
therapy than all other patients combined suggesting a cross-talk between ER and growth 
factor signaling pathways (discussed in Section 3.3.). This work supports the hypothesis 
that increased expression or activation of ER co-activators could enhance the agonist 
activity of tamoxifen and potentially contribute to resistance. 
 
 
3.2.2. Co-repressors 
 
 The co-repressor NCoR has been shown to interact with ER when bound to 4OH-
tamoxifen and acts as part of larger protein complex with histone deacetylase activity that 
promotes chromatin condensation and leads to target-gene silencing [45]. NCoR binds 
avidly to ER in the presence of tamoxifen, but when NCoR activity is blocked with an 
antibody in MCF-7 human breast cancer cells, tamoxifen instead acts as an agonist [49]. 
MCF7 cells were also implanted into ovarectomized, athymic nude mice and the animals 
were subsequently treated with tamoxifen. NCoR levels declined in many of the tumors 
that acquired resistance to tamoxifen, relative to tumors with continued response. This 
data demonstrates that a decrease in expression of NCoR can result in a change in 
tamoxifen activity and potentially contribute to resistance. 
 
Girault et al. analyzed the mRNA expression (RT-qPCR) of NCoR in a well-
defined series of ER-positive breast cancer patients who exclusively received adjuvant 
tamoxifen therapy after surgery. They demonstrated that low expression of NCoR is 
associated with significantly shorter relapse-free survival in tamoxifen treated patients 
[50]. Both this work in vivo and the work in vitro demonstrate a mechanism by which 
down regulation or decreased activity of the co-repressor NCoR can contribute to the 
development of resistance to tamoxifen. 
 
 
3.3. Growth Factor Signaling Pathways 
 
 ER signaling does not exist in isolation within the intracellular environment, and 
many other elements, most notably those comprising growth factor transduction cascades, 
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can influence or be influenced by ER signaling [51]. As previously described, in addition 
to the genomic actions, ER may initiate rapid cellular signaling via direct interaction with 
components of growth factor signaling pathways. Activation of ER via the non-genomic 
pathway outside the nucleus results in phosphorylation, and activation of surface tyrosine 
kinase receptors (such IGF-IR, EGFR, and HER2) and also with cellular kinases and 
adaptor molecules (such as c-Src and PI3K) [10]. Many of these interactions lead to the 
activation of key downstream signaling kinases such as MAPK and AKT, which also 
have the potential to phosphorylate and thereby activate ER itself or its co-activator 
proteins (Figure 3-2) [10]. 
 
Alterations in these signaling cascades have the ability to alter the therapeutic 
responses to anti-estrogenic drugs such as tamoxifen and potentially lead to the 
development of resistance. The inappropriate activation of growth factor signaling 
cascades can potentially occur through an enhanced supply of growth factor ligands, via 
up-regulation or through increased activation of the receptors or their downstream 
signaling cascades [52]. Such changes can potentially stimulate growth and proliferation 
of breast cancer cells independently of ER or via cross-talk with ER, and thereby 
contribute to resistance. 
 
 
3.3.1. EGFR and HER2 
 
Epidermal growth factor receptor (EGFR) and Human epidermal growth factor 
receptor 2 (HER2) are transmembrane receptor tyrosine kinases that signal via MAPK, 
ERK1/2, PI3K, and AKT to stimulate proliferation, differentiation, and cell survival. 
Dysregulation and over-expression of EGFR can lead to transformation of cells in vitro 
and tumor formation in nude mice [53]. “Increased EGFR, its cognate growth factor 
ligands (EGF, TGF-, amphiregulin), or hyper-activation of its signaling elements have 
invariably been associated with anti-hormonal resistance, aggressive clinicopathology, 
disease metastasis, and poor prognosis” [54]. In vitro transfection studies indicate a 
causal role of EGF receptor expression in breast cancer progression to hormone 
independence [55]. Other investigators have demonstrated that acquisition of resistance 
in ER-positive breast cancer cell lines following long term treatment with tamoxifen 
often coincides with over-expression of EGFR and activation of downstream molecules 
[11].  
 
ER is a regulator of the cell-cycle, and estrogen-activated ER results in a negative 
feedback to control cell growth by down-regulating genes involved in proliferation, such 
as EGFR and HER2 [15]. In the presence of estrogen, ER-positive breast cancer cells 
suppress EGFR expression, but tamoxifen, by antagonizing ER, may result in increased 
expression and activation of these signaling pathways. EGFR activates MAPK and AKT 
to stimulate proliferation and cell survival, and these signaling kinases may also 
phosphorylate and thereby activate ER or its co-activator proteins resulting in increased 
expression of ER genes [10]. Two ER regulated genes of note are the EGFR ligands 
amphiregulin and TGF. Through this mechanism, tamoxifen may enhance the 
transcription of these ligands creating an autocrine loop that maintains cell growth and  
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Figure 3-2. ER crosstalk with growth factor receptor pathways. This signaling 
diagram illustrates the potential crosstalk between ER and many of the growth factor 
pathways discussed that potentially contribute to tamoxifen resistance in breast cancer.  
 
Reprinted with permission. Massarweh, S. and R. Schiff, Unraveling the mechanisms of 
endocrine resistance in breast cancer: new therapeutic opportunities. Clin Cancer Res, 
2007. 13(7): p. 1950-4 [10].  
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proliferation despite tamoxifen treatment [56]. An example of an autocrine signaling loop 
resulting in cell growth despite anti-hormone treatment is depicted in Figure 3-3. 
 
There is substantial evidence supporting the up-regulation of EGFR as a 
mechanism for the enhanced cross talk with ER; however, another group has 
demonstrated another potential mechanism to enhance the interaction between EGFR and 
ER [57]. Fan et al. demonstrated that long-term exposure of hormone-sensitive MCF-7 
breast cancer cells to tamoxifen causes cytoplasmic translocation of ER. They report 
that the elevation in the levels of extra-nuclear ER increases the opportunity of ER to 
associate with factors that facilitate activation of the MAPK pathway. The enhanced 
interaction between ER and EGFR is associated with an increased ability of EGF, 
estrogen and tamoxifen to stimulate MAPK, and tamoxifen elicited rapid phosphorylation 
of MAPK in resistant cells in contrast to its antagonistic activity in control cells [57]. 
Their results further support that enhanced non-genomic function of ER via cooperation 
with the EGFR pathway represents a mechanism responsible for acquired tamoxifen 
resistance. 
 
HER2 has also been implicated in de novo resistance to tamoxifen. Breast cancer 
patients whose ER-positive tumors express high levels of the co-activator AIB1 and 
HER2 treated with tamoxifen experience substantially more recurrences than those with 
ER-positive tumors that have lower expression of one or both proteins [46]. Tamoxifen 
acts as an antagonist in parental MCF-7 cells, which express high AIB1 but low HER2 
expression, and tamoxifen behaves as an agonist in MCF-7 cells expressing high levels of 
both HER2 and AIB1 [58]. This agonist activity on gene expression and cell proliferation 
resulted in tumor growth stimulation by tamoxifen demonstrating de novo resistance. In 
this intracellular environment, tamoxifen-bound ER recruits the co-activator rather than 
co-repressors, resulting in agonist activity [15]. Both the clinical and in vitro data indicate 
that both HER2 and AIB1 are necessary for this resistant phenotype. This mechanism of 
resistance is also a function of enhanced cross-talk as the enhanced signaling of HER2 
results in the phosphorylation and activation of both ER and the co-activator AIB1. The 
agonist effect of tamoxifen in the resistant cells is reversed by administration of gefitnib, 
a tyrosine kinase inhibitor [58]. Gefitnib restores the recruitment of co-repressor 
complexes by tamoxifen-bound ER resulting in a return of the antagonistic effects. 
 
 
3.3.2. IGF-1R 
 
The role of IGF signaling in tamoxifen resistance is much less clear than that of 
EGFR and HER2, but evidence for a role of IGF-1R is emerging [11]. IGF-1R is also a 
member of the receptor tyrosine kinase family, and it is activated after ligand binding of 
insulin, IGF-I, or IGF-II resulting in the activation of downstream signaling pathways 
including AKT, MAPK and PI3K cascades [58].   As previously discussed these 
signaling pathways have been shown to influence cell survival and proliferation. IGF-IR 
is an ER-dependent gene and tamoxifen, which effectively inhibits classically ER-
dependent transcription, can effectively reduce its expression [59]. The data regarding the  
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Figure 3-3. Autocrine signaling loop counteracting the anti-proliferative effect of 
endocrine therapy. Anti-estrogen treatment may result in an increase of EGFR/HER2 
expression. These receptor tyrosine kinases activate the downstream MAPK/AKT 
signaling cascade, which phosphorylate and activate nuclear ER in the absence of ligand. 
Persistent ER activation leads to increased transcription of ER-sensitive genes, including 
amphiregulin and TGF, which also activate EGFR completing the autocrine proliferative 
loop. The net effect is a reduction or elimination of the anti-proliferative effect of 
endocrine therapy.  
 
Reprinted with permission. Zilli, M., et al., Molecular mechanisms of endocrine 
resistance and their implication in the therapy of breast cancer. Biochim Biophys Acta, 
2009. 1795(1): p. 62-81 [15].  
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levels of IGF-1R in tamoxifen-resistant breast cancer lines is mixed, however there is 
increasing evidence supporting synergistic interactions between IGF-1R, ER and EGFR. 
Estrogens result in an increase in expression of the IGF-IR and growth, while IGFs prime 
the activation of several kinases that are able to phosphorylate ER and initiate estrogen-
mediated gene expression [58].  
 
 One mechanism by which IGF-1-treated breast cancer cells may escape 
tamoxifen-induced apoptosis is via the IGF-mediated activation of AKT and subsequent 
phosphorylation of ER leading to the ligand-independent activation of ER [60]. Recent in 
vitro studies have aimed at elucidating the role of IGF-1R in breast cancer resistance. 
Unlike EGFR, several studies have reported that tamoxifen continues to suppress IGF-1R 
level even during the development of resistance. However, Massarweh et al. discovered 
that p-IGF-IR, although initially reduced in the tamoxifen-sensitive tumors, is increased 
at the time of resistance, suggesting that IGF-IR becomes activated at the time of 
acquired resistance and then augments important cell survival pathways [59]. It has also 
been shown that inhibition of IGF-1R (by an anti-IGF-1R antibody [61] or by an IGF-1R 
tyrosine kinase inhibitor [58]) reduces growth of tamoxifen-resistant MCF-7 breast 
cancer cells. An in vivo model also demonstrated that an IGF-1R monoclonal antibody 
enhances the anti-tumor activity of tamoxifen in estrogen receptor positive breast cancer 
xenografts [62].  
 
Data also suggest that bi-directional crosstalk pathways between the epidermal 
growth factor family of receptors (erbB) and IGF-1R exists, and this interaction has been 
suggested to in part mediate the development of acquired resistance. In vitro work has 
shown that increased IGF-IR signaling interferes with the action of the HER-2 antibody 
trastuzumab in HER2 positive breast cancer cells [63]. Similarly, these breast cancer cells 
displayed enhanced cytotoxic effects when cultured with trastuzumab and an anti-IGF1 
receptor antibody in combination [64]. Both activated EGFR and HER2 are also 
sufficient for conferring resistance to an IGF-1R inhibitor [65]. These data suggest that 
alterations to both the IGF-1R and erbB receptor pathways may occur in a reciprocating 
fashion leading to resistance [66]. The mechanism by which IGF may interact with EGFR 
and ER in breast cancer cells is becoming clearer; however, to date no conclusive clinical 
data has been reported regarding the clinical significance of IGF-IR’s role in tamoxifen 
resistance. 
 
 
3.3.3. Cas, c-Src and BCAR 
 
Several cytoplasmic proteins whose functions are also coupled to growth factor 
receptors have been connected to tamoxifen resistance. In particular, BCAR and Cas are 
two implicated proteins that were discovered in a screening to identify proteins capable 
of inducing anti-estrogen resistance in vitro [11]. It has since been noted that patients 
with primary breast tumors expressing high levels of Cas protein are associated with 
more rapid disease recurrence and have a greater risk of (intrinsic) resistance to 
tamoxifen [67].  
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3.3.3.1 Cas and c-Src 
 
High expression of Cas (p130Cas) is associated with resistance to tamoxifen in 
both tissue culture and in human tumors. Cas is a scaffold protein that assists in the 
formation of multi-protein complexes, by promoting protein-protein interactions [68]. It 
is an important aspect of signal transduction pathways that modulate cell motility, 
survival and proliferation. Riggins et al. demonstrated that Cas binds to and activates c-
Src, a protein tyrosine kinase and results in phosphorylation of c-Src substrates, such as 
EGFR and signal transducer and activator of transcription (STAT) 5b. Inhibition EGFR 
and STAT5b abrogates the effect of Cas overexpression, supporting the significance of 
these c-Src substrates in the development of resistance [69]. Pharmacologic inhibition of 
c-Src in MCF-7 cells also enhances the inhibitory effects of tamoxifen on cell growth 
[70]. It is clear that Cas overexpression diminishes the anti-proliferative and pro-
apoptotic effects of tamoxifen on breast cancer cells in vitro, and data suggests it 
accomplishes this via the activation of the Cas/c-Src/EGFR/STAT5 signaling pathway. 
 
Whether these pathways are also clinically significant in resistance to tamoxifen 
has not yet been established; however, a large percentage of human breast tumors express 
high levels of both c-Src and Cas, as well as elevated c-Src kinase activity, and “c-
Src/Cas complexes can be isolated from a majority of breast cancer cell lines” [11]. 
These data together suggest that tamoxifen resistance may be mediated in part through 
this mechanism involving c-Src and Cas. 
 
 
3.3.3.2 BCAR3 
 
Breast cancer anti-estrogen resistance 3 (BCAR3) was discovered in a genetic 
screening for genes associated with anti-estrogen resistance. It encodes a component of 
intracellular signal transduction and interacts directly with Cas. Transfer of the BCAR3 
gene by cell fusion or transfection to breast cancer cells induces anti-estrogen resistance 
suggesting that up-regulation of BCAR3 (also knowns as AND-34) stimulates an 
alternative growth path independent of hormone, both in the presence and absence of 
anti-estrogens [71]. BCAR3 has since been shown to alter the activity, expression, and 
intracellular location of many proteins, including Cas, Ras and Rho family GTPases, and 
Pak1 [11]. Work by Felekkis et al. showed BCAR3 over-expression induced anti-
estrogen resistance in human breast cancer cell lines by activating PI3K, which induced 
Rac activation and finally resulted in anti-estrogen resistance [72]. While the data suggest 
that BCAR3 over-expression has the potential to result in resistance in cultured cells, the 
role of BCAR3 in the clinical setting of resistance has not yet been established. 
 
 
3.3.4. PI3K and AKT 
 
 Downstream of growth factor receptors and adapter protein activation, signaling 
intermediates such as AKT play an important role in cell proliferation, survival, and 
endocrine resistance [11]. Receptor tyrosine kinases, such as the growth factor receptors 
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EGFR and IGF-1R, activate PI3K, which in turn activates AKT, leading to substrate 
phosphorylation. The tumor suppressor PTEN antagonizes AKT and acts as a counter 
balance acting as a phosphatase. AKT activation promotes cell survival by inhibiting 
apoptosis and also plays a roll in regulation of the cell cycle. Over-expression of 
constitutively active AKT in MCF-7 breast cancer cell lines results in estrogen 
independence and resistance to tamoxifen [73], and activation of AKT is increased in 
tamoxifen-resistant MCF-7 breast cancer cells [74]. The exact mechanisms by which 
AKT may confer anti-estrogen resistance are unclear. 
 
Phosphorylation of ER by AKT is one proposed mechanism demonstrated in vitro 
to result in decreased sensitivity to tamoxifen. Phosphorylation of Ser-167 by AKT 
results in increased ER binding to DNA and increased recruitment of the co-activator 
SRC3 potentially resulting in increased agonism [75]. In ER-positive breast cancer cell 
lines, PI3K-mediated AKT phosphorylation of ER results in receptor activation in the 
absence of estrogen [60]. AKT has also been shown to enhance co-activator recruitment 
to ER and to potentiate ER transcriptional activity [60]. Evidence from in vitro studies 
supports a role of AKT-mediated phosphorylation of ER, but the clinical significance in 
tamoxifen resistance remains unclear. 
 
AKT can also indirectly activate mTOR which also controls cell growth, survival, 
and apoptosis [76]. In response to activation by growth factor receptors, AKT 
phosphorylates and inactivates the tuberous sclerosis complex, which acts as a negative 
regulator of mTOR. Blockage of the PI3K/AKT signaling pathway by pharmacologic 
mTOR inhibition successfully restores the effectiveness of tamoxifen in MCF-7 breast 
cancer cells with constitutively active AKT [77]. While a definitive role of mTOR in 
resistance has not been determined, mTOR is considered an attractive therapeutic target 
for treating breast cancer [11]. 
 
 
3.3.5. Stress-Activated Protein Kinase/c-Jun Kinase Pathway 
 
 Jun NH2-terminal kinases (JNKs) and stress activated protein kinases (SAPKs), 
which are activated by cellular stresses, increase AP-1 transcriptional activity via 
phosphorylation. AP-1 is a transcription factor heterodimer composed of Jun and Fos 
family members, which binds to DNA at AP-1 response elements [78]. In vitro work has 
demonstrated that the development of tamoxifen resistance is accompanied by increased 
AP-1 DNA binding [79]. Johnston et al. examined a panel of 30 ER-positive primary 
human breast tumors with acquired tamoxifen resistance, and these tumors also displayed 
a significant increase in AP-1 DNA binding activity when compared to untreated control 
tumors [80]. In a tamoxifen-resistant xenograft model, increased phosphorylated c-Jun 
and JNK levels accompanied the increase in AP-1 dependent transcription following 
tamoxifen treatment, and the conversion to a resistant phenotype was associated with an 
increase in oxidative stress [81]. It is known that tamoxifen can induce intracellular 
oxidative stress, and this data supports the model in which tamoxifen-induced oxidative 
stress leads to activation of JNK and SAPK resulting in increased AP-1 activity and could 
contribute to resistance [17]. 
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3.4. Cell Cycle Regulators 
 
 Cyclins, cyclin-dependent kinases (CDKs), and CDK inhibitors are the major 
regulators of cell cycle progression [11]. Estrogen accelerates the progression from G1 to 
S phase, while tamoxifen inhibits cell cycle progression by affecting these key cell cycle 
proteins [82]. These expression and activity of these proteins have been demonstrated to 
have the potential to significantly impact tamoxifen sensitivity and resistance. 
 
 
3.4.1. Cyclin D1 
  
 Essential for early progression through the G1 phase, cyclin D1 both modulates 
CDK4/6-dependent phosphorylation of the tumor suppressor Rb and sequesters the CDK 
inhibitors p21 and p27 [11]. Cyclin D1 is a direct transcriptional target of estrogen 
signaling, and therefore tamoxifen reduces cyclin D1 expression [83]. In vitro sustained 
expression of cyclin D1 is evident in breast cancer cells during their acquisition of 
tamoxifen resistance [84], and down-regulation of cyclin D1 with siRNA restored the 
sensitivity of these cells to tamoxifen [85]. Cyclin D1can potentiate the transcriptional 
activity of the ER independently of estrogen and may not be inhibited by tamoxifen [86]. 
Clinical studies also support the role of cyclin D1 in tamoxifen resistance. Patients with 
cyclin D1 negative tumors show better relapse free survival on tamoxifen, and cyclin D1 
expression is correlated with a poorer outcome of tamoxifen treatment [87]. Multiple 
clinical studies have demonstrated that breast cancer patients also show that cyclin D1 
over-expression correlates with poor outcome on tamoxifen treatment [88, 89]. 
 
 
3.4.2. Cyclin E 
 
 Cyclin D1 inhibits Rb early in G1 phase, and the transcription factor E2F strongly 
induces the expression of cyclin E, which associates with CDK2 to form an active 
complex that promotes entry into S phase [90]. Cyclin E and CDK2 activity is 
antagonized by the CDK inhibitors p21 and p27. The contribution of cyclin E to 
tamoxifen resistance is unclear, but over-expression of cyclin E in MCF-7 cells partially 
counteracts the growth arrest mediated by tamoxifen [91]. More studies are necessary to 
determine the mechanisms by which cyclin E is induced in breast cancer and its role in 
the induction of resistance.  
 
 
 
3.4.3. p21 and p27 
 
 p21 and p27 are CDK inhibitors and are negative regulators of cell cycle 
progression. These proteins counteract the activities of cyclin D1 and cyclin E. In MCF- 
7 cells, tamoxifen increase the expression of p21 and p27 during cell cycle arrest, but 
down-regulation of these by antisense inhibition prevents the growth inhibitory effects 
[92]. p27 induction in breast cancer cells by tamoxifen induces quiescence and 
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insensitivity to growth stimulation by growth factors such as IGF-I and EGF [93]. 
Somatic deletion of the p21 gene in human breast cancer cells resulted in 
hyperphosphorylation of ER causing an increased gene expression of ER regulated 
genes [94]. These studies demonstrate that p27 and p21 are critical for the inhibitory 
effects of tamoxifen in inhibiting breast cancer cell growth.  
 
c-Myc, a transcription factor whose expression is frequently altered in human 
breast cancer, also plays a role in regulating the activity of p21. Increased c-Myc 
expression can rescue the growth arrest mediated by anti-estrogen treatment by activating 
CDK2/Cyclin E complex [95]. In vitro over-expression of c-Myc reduces the expression 
of p21 in response to tamoxifen potentially mediating tamoxifen resistance [96]. They 
also demonstrate that p21 expression in anti-estrogen resistant cells is increased when 
treated with c-Myc siRNAs. 
 
Clinical data also supports a role of these CDK inhibitors in response to 
tamoxifen treatment. In premenopausal women with early breast cancer, an increase in 
p27/KIP1 expression was able to predict better relapse free survival upon tamoxifen 
combination treatment [97]. A multivariate analysis of their data revealed decreased p27 
expression to be correlated with poor outcome upon combination endocrine therapy. 
Localization of these CDK inhibitors has also been implicated in the development of 
resistance. Perex-Tenorio et al. showed that increased activity of the PI3K and MAPK 
pathway promotes p21 localization into cytoplasm through phosphorylation of residues 
within their nuclear localization sequences [98]. The significance of their in vitro data is 
supported by immunohistochemistry in frozen human tumors. They demonstrated that 
increased cytoplasmic localization of p21 is correlated with a poorer response to 
tamoxifen treatment in a cohort of 280 women.  
 
 
3.5. c-ABL 
 
 c-ABL is a non–receptor tyrosine kinase with multiple functions in the regulation 
of cell migration, responses to oxidative stress and DNA damage, cell proliferation, and 
survival [99]. The oncogenic potential of c-ABL was first discovered in leukemias, but 
has recently been found it is not confined to hematopoietic malignancies [100]. Studies 
now indicate that c-ABL has a potential role in breast carcinogenesis. Zhao et al. 
demonstrated that c-ABL interacts with ER resulting in enhanced ER activity and 
together promote resistance to tamoxifen [100]. They report that c-ABL is required for 
maintaining ER transcriptional activity and that silencing c-ABL results in the 
sensitization of ER-positive breast cancer cells to tamoxifen treatment. They report that 
the expression of c-ABL is a frequent event in primary breast cancer tumor tissues, and 
the expression of c-ABL in ER-positive tumors is significantly correlated with disease 
progression and metastasis. This work suggests c-ABL as a potential therapeutic target 
and prognostic tumor marker for breast cancer. 
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CHAPTER 4. CONCLUSION 
 
 
Endocrine treatment of ER-positive breast cancer with tamoxifen, and later on 
with aromatase inhibitors and fulvestrant, was the first target-based therapeutic strategy 
in oncology [101]. Unfortunately, a substantial proportion of patients, despite being ER 
and/or PR positive, are either primarily resistant or will develop resistance during the 
course of their disease. Delineation of the molecular mechanisms underlying the 
development of resistance will allow development of treatment strategies to enhance 
response and compromise resistance.  
 
It has become apparent that ER transcriptional actions are not just determined by 
the ligand, but also by complex interactions between co-regulatory molecules and 
multiple signaling pathways, which provide several potential mechanisms by which 
cancer cells may become estrogen-independent and tamoxifen-resistant [17]. 
Experimental models have demonstrated that the development of resistance is 
accompanied by the many mechanisms discussed. Clinical data further support several of 
these mechanisms. Further elucidation of the clinically relevant pathways of resistance, 
biomarkers reflecting the activity of these pathways and surrogate biomarkers predictive 
of response are therefore critical to determine which therapeutic strategies should be 
tested [102]. Some pharmacological agents targeting these pathways are currently 
clinically available and others are in development, but it is imperative to remember that 
there are likely to be several clinically significant pathways to resistance and that some 
will be important in certain patients but irrelevant in others. Gene expression analysis and 
molecular profiling have increased our understanding of the mechanisms of response and 
resistance, and these approaches are currently being used to develop gene signatures that 
may predict clinical responses to treatment [11]. 
 
Resistance to SERMs, aromatase inhibitors, and SERDs are likely to be mediated 
by distinct pathways, which explains the lack of cross-resistance between the different 
classes of drugs [15]. Therefore, the sequential use of endocrine agents is the supported 
treatment plan, but the currently available clinical, experimental, and pharmacokinetic 
data do not support the concomitant use of hormonal agents [15]. However, 
combinatorial therapies of tamoxifen (or other hormonal agents) with drugs aimed at the 
signaling pathways underlying the development of resistance may be a potential means of 
delaying the onset of resistance. A number of clinical trials have sought to determine 
whether the addition of signal transduction inhibitors to endocrine therapy may overcome 
endocrine resistance or delay its development [102]. Trials using HER2/neu antagonists, 
tyrosine kinase inhibitors, multikinase inhibitors, src inhibitors, and mTOR antagonists 
are currently underway in the treatment of breast cancer. Despite an improved 
understanding, resistance to all forms of endocrine therapy remains a significant clinical 
problem. A clearer understanding of the clinically significant mechanisms by which 
resistance develops is critical for improving the treatment of patients with breast cancer 
as well as in the development of new drugs and optimal treatment strategies.  
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